China

News

Kelun-Biotech first to bag TROP2 approval in lung cancer

Kelun-Biotech wins first global regulatory approval - in China - for a TROP2-directed antibody-drug conjugate (ADC) in lung cancer.

R&D

Will 2025 be the year the pharmaceutical industry finds its ...

After spending 2024 in recovery mode, the biopharma industry is finally showing signs of growth, climbing back toward its pre-pandemic heights.

R&D

Clinical trends for 2025: A year of change

After 2024, which saw a steady recovery by the life sciences industry, it looks like 2025 is set to be a year of change and development, particularly in clinical trials.

News

Pressure relieved on AZ as details of Chinese probe emerge

AstraZeneca's exposure to liability in a Chinese investigation into illegal drug imports appears to be much less than had been feared.

News

Hand pointing to viewer through map of China

Trump tariffs 'would strain the pharma supply chain'

Pharma organisations in the US have said that Trump's tariffs plan could drive up the cost of generics, block supply chains and worsen drug shortages.

R&D

5 takeaways from JP Morgan 2025

I’m back from another week in San Francisco, where as usual I heard from experts and prognosticators about their expectations for the coming year in biotech.

Kelun-Biotech first to bag TROP2 approval in lung cancer

Will 2025 be the year the pharmaceutical industry finds its ...

Clinical trends for 2025: A year of change

Pressure relieved on AZ as details of Chinese probe emerge

Trump tariffs 'would strain the pharma supply chain'

5 takeaways from JP Morgan 2025

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

China

Editor's Picks